Supernus Pharmaceuticals Files 8-K for Shareholder Vote & Exhibits

Ticker: SUPN · Form: 8-K · Filed: 2025-06-17T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, financial-reporting, shareholder-vote

Related Tickers: SUPN

TL;DR

SUPN filed an 8-K for shareholder votes and financials - check for updates.

AI Summary

On June 16, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report to announce the submission of matters to a vote of security holders and to file financial statements and exhibits. The filing was made on June 17, 2025, and pertains to the company's operations as of June 16, 2025. Supernus Pharmaceuticals, Inc. is incorporated in Delaware and its principal executive offices are located in Rockville, MD.

Why It Matters

This filing indicates that Supernus Pharmaceuticals is proceeding with important corporate actions requiring shareholder approval and is providing updated financial information, which is crucial for investors to assess the company's governance and financial health.

Risk Assessment

Risk Level: low — This is a routine filing for corporate governance and financial reporting, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific matters are being submitted for a vote of security holders?

The filing indicates that matters are being submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What financial statements and exhibits are being filed?

The filing states that financial statements and exhibits are being filed, but the specific content of these documents is not detailed in the provided text.

What is the significance of the 'Date as of change' being June 17, 2025?

The 'Date as of change' being June 17, 2025, likely refers to the date the filing was officially processed or updated in the SEC system, aligning with the filing date.

What is Supernus Pharmaceuticals, Inc.'s primary business?

Supernus Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st (1231).

From the Filing

0001356576-25-000042.txt : 20250617 0001356576-25-000042.hdr.sgml : 20250617 20250617164035 ACCESSION NUMBER: 0001356576-25-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250616 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250617 DATE AS OF CHANGE: 20250617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 251053883 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20250616.htm 8-K supn-20250616 false 0001356576 0001356576 2025-06-16 2025-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 16, 2025   Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07             Submission of Matters to a Vote of Security Holders. On June 16, 2025 Supernus Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 30, 2025. As of the close of business on April 22, 2025, there were 55,989,623 shares of common stock outstanding and entitled to vote. The tabulation of votes for ea

View on Read The Filing